Users Online: 358
Home Print this page Email this page
Home About us Editorial board Search Browse articles Submit article Ahead of Print Instructions Subscribe Contacts Login 


 
Previous article Browse articles Next article 
LETTER TO EDITOR
Adv Biomed Res 2018,  7:115

Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial”


Department of Pharmacology, Dr. DY Patil Medical College, Navi Mumbai, Maharashtra, India

Date of Web Publication22-Jan-2018

Correspondence Address:
Dr. Anant D Patil
Department of Pharmacology, Dr. DY Patil Medical College, Navi Mumbai - 400 706, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/abr.abr_81_18

Rights and Permissions

How to cite this article:
Patil AD. Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial”. Adv Biomed Res 2018;7:115

How to cite this URL:
Patil AD. Response to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial”. Adv Biomed Res [serial online] 2018 [cited 2018 Dec 14];7:115. Available from: http://www.advbiores.net/text.asp?2018/7/1/115/237274



Sir,

I read with a great interest the article titled, “Levofloxacin-containing versus clarithromycin-containing therapy for Helicobacter pylori eradication: A prospective randomized controlled clinical trial”[1] authored by Sebghatollahi et al. I would like to compliment the authors for conducting a study on a widely prevalent disease with a very good design.

The results of this study provide many insights about the management of H. pylori infection in the current scenario.

In the inclusion criteria, the authors have mentioned that patients with peptic ulcer disease were included; however, it seems many patients in the study did not have gastric/duodenal ulcer. It looks like patients with H. pylori infection with peptic ulcer disease or dyspepsia both were included.

Although there was no significant difference in two groups, many findings including numerically higher eradication rate, lower incidence of self-reported adverse events, and severe intolerance are in favor of the pantoprazole, bismuth subcitrate, amoxicillin and clarithromycin (PBAC), i.e., clarithromycin-containing group. In the absence of significant difference between the two groups, comparative data on compliance of two regimens may be useful for a clinical decision of selecting one regimen over the other. If medicines are not provided in the kit, there are chances of lesser compliance in the pantoprazole, bismuth subcitrate, amoxicillin 1 g, tinidazole for 7 days, followed by levofloxacin for next 7 days (PBATL) group, because patients need to change from tinidazole to levofloxacin after a week unlike in the PBAC group where therapy was same for 14 days.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus clarithromycin-containing therapy for Helicobacter pylori eradication: A prospective randomized controlled clinical trial. Adv Biomed Res 2018;7:55.  Back to cited text no. 1
[PUBMED]  [Full text]  




 

Top
Previous article  Next article
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed228    
    Printed6    
    Emailed0    
    PDF Downloaded56    
    Comments [Add]    

Recommend this journal